124 results
The purpose of this study is to demonstrate improvement in Disease-Free Survival (DFS) with xevinapant compared to placebo when added to RT irrespective of subsequent anticancer therapy.
• Evaluate antitumor activity based on response assessment criteria (RECIST v1.1)• Determine RP2D (unless determined in the Escalation part)
Primary objectives:# Safety Lead-in Phase: To assess the safety and tolerability, and to establish an RP2D if applicable, of treatment combinations that have not been evaluated in a separate study.# Efficacy Phase: To assess the safety and…
The primary objective of this proof-of-concept study is to evaluate feasibility of 68Ga-tilmanocept PET/CT for SLN mapping in patients with stage I-II high/high-intermediate risk endometrial cancer. Secondary objectives are: - To investigate the…